论文部分内容阅读
目的:研究子痫前期及子痫患者的中期因子的表达及临床意义。方法:选取我院2009年1月-2010年12月产科住院的轻度子痫前期、重度子痫前期-子痫患者各60例,同期住院的正常妊娠晚期妇女60例,检测各组母体血清中期因子含量和记录孕产妇及围生儿并发症情况。结果:轻度子痫前期时母体血清MK表达明显升高,与正常妊娠晚期组相比较有统计学意义(P<0.01);重度子痫前期-子痫时MK表达明显降低,与正常妊娠晚期组、轻度子痫前期组相比较,有统计学意义(P<0.01)。三组母体及围生儿并发症相比较,有统计学意义(P<0.05)。结论:MK可作为疾病的监测和预后的重要指标,可成为该病治疗的新途径。
Objective: To study the expression of midkine and its clinical significance in patients with preeclampsia and eclampsia. Methods: 60 cases of mild preeclampsia and severe preeclampsia-eclampsia hospitalized in our hospital from January 2009 to December 2010 were enrolled in this study. Sixty normal pregnant women were enrolled in the same period. 60 cases of maternal serum Mid-term factor content and record maternal and perinatal complications. Results: The expression of MK in maternal serum of mild preeclampsia group was significantly higher than that of normal pregnancy group (P <0.01), while the expression of MK in severe preeclampsia-eclampsia was significantly lower than that in normal pregnancy stage Group, mild preeclampsia group, there was statistical significance (P <0.01). Three groups of maternal and perinatal complications, compared with statistical significance (P <0.05). Conclusion: MK can be used as an important indicator of disease surveillance and prognosis, which may become a new approach to the treatment of this disease.